Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mepivacaine
Drug ID BADD_D01387
Description A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
Indications and Usage For production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
Marketing Status approved; vet_approved
ATC Code N01BB03
DrugBank ID DB00961
KEGG ID D08181
MeSH ID D008619
PubChem ID 4062
TTD Drug ID D0WO8W
NDC Product Code 52932-0745
UNII B6E06QE59J
Synonyms Mepivacaine | Mepivacaina Braun | Isogaine | Meaverin | Mecain | Mepihexal | Mepivacain-Injektopas | Mepivacain Injektopas | Mepivacaine Hydrochloride | Mepivacaine Monohydrochloride | Mepivastesin | Polocaine | Scandinibsa | Scandonest | Scandicain | Scandicaine | Carbocaine | Carbocaïne | Isocaine
Chemical Information
Molecular Formula C15H22N2O
CAS Registry Number 96-88-8
SMILES CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysphonia19.19.03.002; 17.02.08.004; 22.12.03.0060.000179%
Dyspnoea02.11.05.003; 22.02.01.0040.001822%
Erythema23.03.06.0010.000482%Not Available
Eyelid ptosis17.17.02.004; 06.05.01.0020.000179%Not Available
Face oedema10.01.05.002; 08.01.07.003; 23.04.01.0040.000179%
Feeling abnormal08.01.09.0140.000179%Not Available
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.0280.000268%
Hypersensitivity10.01.03.0030.000786%
Hypertension24.08.02.0010.000536%
Hypoaesthesia17.02.06.023; 23.03.03.0810.000572%Not Available
Hypotension24.06.03.0020.000179%
Injection site pain12.07.03.011; 08.02.03.0100.000607%Not Available
Laryngeal oedema22.04.02.001; 10.01.05.003; 23.04.01.0050.000179%
Loss of consciousness17.02.04.0040.000357%Not Available
Malaise08.01.01.0030.000840%
Meningism17.02.05.007--
Meningitis17.06.03.001; 11.01.03.001--
Nausea07.01.07.001--
Nervous system disorder17.02.10.0010.000179%Not Available
Nervousness19.06.02.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oral discomfort07.05.05.0010.001000%Not Available
Pain in jaw15.02.01.0030.000179%Not Available
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.000179%Not Available
Palpitations02.11.04.0120.000179%
Paraesthesia23.03.03.094; 17.02.06.0050.000482%
Paralysis17.01.04.004--Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.000179%
Pruritus23.03.12.001--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages